SCHEMBL285617

SCHEMBL285617

CCOC(=O)c1c(C2CCOCC2)noc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.40
CACNA1F O60840 2/20 0.40
CACNA1D Q01668 2/20 0.40
CACNA1S Q13698 2/20 0.40
CACNA1C Q13936 2/20 0.40
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
KDM4E B2RXH2 4/20 0.38
CYP1A2 P05177 1/20 0.38
LMNA P02545 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HTT P42858 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
POLB P06746 1/20 0.38
TSHR P16473 3/20 0.37
HSD17B10 Q99714 2/20 0.37
USP2 O75604 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL285476 0.89 L3MBTL1 (0.45) ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C
SCHEMBL285668 0.87 L3MBTL1 (0.44) ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C
SCHEMBL19900019 0.86 TSHR (0.37) ALDH1A1L3MBTL1KDM4ELMNAMEN1
SCHEMBL2006487 0.76 ADORA3 (0.40) ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C
SCHEMBL19900847 0.74 ADORA3 (0.39) ALDH1A1L3MBTL1KDM4ELMNAMEN1
SCHEMBL31706396 0.72 MMP2 (0.40) ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C
SCHEMBL27006476 0.72 TSHR (0.50) ALDH1A1LMNASMN1; SMN2POLBTSHR
SCHEMBL2775305 0.72 ALDH1A1 (0.58) ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C
SCHEMBL15885600 0.71 PDE4B (0.46) ALDH1A1KDM4ELMNAPOLBPDE4B
SCHEMBL16210583 0.71 TSHR (0.41) ALDH1A1L3MBTL1KDM4ECYP1A2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427457-B1 ISOXAZOLE-PYRIDINE DERIVATIVES AS GABA MODULATORS HOFFMANN LA ROCHE (CH) 2013-07-17 EP disclosed
US-8357703-B2 Pyridines HOFFMANN-LA ROCHE INC. (US) 2013-01-22 US disclosed
US-8163728-B2 Pyrazoles HOFFMANN-LA ROCHE INC. (US) 2012-04-24 US disclosed
EP-2427457-A1 ISOXAZOLE-PYRIDINE DERIVATIVES AS GABA MODULATORS F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
EP-2427455-A1 ISOXAZOLE-PYRAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
US-20100286115-A1 PYRAZOLES ROCHE PALO ALTO LLC 2010-11-11 US disclosed
US-20100286117-A1 PYRIDINES ROCHE PALO ALTO LLC 2010-11-11 US disclosed
WO-2010127975-A1 ISOXAZOLE-PYRAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO disclosed
WO-2010127978-A1 ISOXAZOLE-PYRIDINE DERIVATIVES AS GABA MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286115-A1 PYRAZOLES GABRA5, GABRA1, GABRA3 ALDH1A1 724/4885CACNA1F 271/4885CACNA1D 327/4885
US-20100286117-A1 PYRIDINES GABRA5, GABRA1, GABRA4 ALDH1A1 459/4885CACNA1F 291/4885CACNA1D 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.